A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
for
Melanoma
Location: Durham NC
Sponsor: Duke University
Sex: All
Age: 18+
Code: NCT05077137
Phase1, Recruiting
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
for
Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma,
Location: Tampa FL
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Sex: All
Age: 18+
Code: NCT06295159
Phase2, Recruiting
Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma
for
Melanoma
Location: Las Vegas NV
Sponsor: Wolfram Samlowski
Sex: All
Age: 18+
Code: NCT01565837
Phase2, Recruiting
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma
for
Melanoma, Dysplastic Nevus Syndrome
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 0 - 70+
Code: NCT00040352
Recruiting
RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
for
Melanoma
Location: Pittsburgh PA
Sponsor: Yana Najjar
Sex: All
Age: 18+
Code: NCT06216938
Early_phase1, Recruiting
BostonGene and Exigent Genomic INsight Study
for
Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Sarcoma
Location: Fort Wayne IN, Rogers AR, Houston TX, Tulsa OK,
Sponsor: BostonGene
Sex: All
Age: 18+
Code: NCT06272864
Recruiting
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients
for
Melanoma Stage III, Melanoma Stage IV
Location: Hartford CT, New York NY
Sponsor: Philogen S.p.A.
Sex: All
Age: 18+
Code: NCT06284590
Phase2, Recruiting
Molecular Analysis of Childhood and Adolescent Melanocytic Lesions
for
Melanoma
Location: Memphis TN
Sponsor: St. Jude Children's Research Hospital
Sex: All
Age: 0 - 18
Code: NCT02775643
Recruiting
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
for
Melanoma
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18 - 70+
Code: NCT02621021
Phase2, Recruiting
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067